Copyright: ©Author(s) 2026.
World J Stem Cells. Oct 26, 2026; 18(10): 124640
Published online Oct 26, 2026. doi: 10.4252/wjsc.124640
Published online Oct 26, 2026. doi: 10.4252/wjsc.124640
Figure 1 Characterization of human bone-marrow-derived mesenchymal stem cells.
A: Representative bright-field image showing the morphology of human bone-marrow-derived mesenchymal stem cells (hBMSCs); B: Alizarin Red S staining; C: Oil Red O staining; D: Surface marker profiling of hBMSCs by flow cytometry. Mesenchymal stem cells showed higher levels of CD73, CD90, and CD105, and lower levels of CD34; E: Representative images of the DiI-labeled hBMSCs; F: The fluorescence imaging of different organs. hBMSCs: Human bone-marrow-derived mesenchymal stem cells.
- Citation: Liu Y, Wu JF, Xu MY, Kang J, Ye AH, Liu B, Liu KZ. Human bone marrow-derived mesenchymal stem cells alleviate fluoxetine-resistant depression-like behaviors in mice by multi-target effects in the hippocampus. World J Stem Cells 2026; 18(10): 124640
- URL: https://www.wjgnet.com/1948-0210/full/v18/i10/124640.htm
- DOI: https://dx.doi.org/10.4252/wjsc.124640